<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054779</url>
  </required_header>
  <id_info>
    <org_study_id>PKE COMIT II</org_study_id>
    <nct_id>NCT03054779</nct_id>
  </id_info>
  <brief_title>Canola Oil Multi-center Intervention Trial II</brief_title>
  <acronym>COMITII</acronym>
  <official_title>Canola Oil Multi-center Intervention Trial II (COMIT II): Effects of Oleic Acid Enriched and Regular Canola Oil on Body Composition and Lipid Metabolism in Participants With Metabolic Syndrome Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canola Council of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Boniface General Hospital Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Building on the findings from the investigators previous study, COMIT I, the purpose of the
      COMIT II study is to supplement the DEXA measurement of body composition with a supplementary
      DEXA measurement of visceral adipose tissue and to specifically target the impact of oleic
      acid consumption on body composition as the primary objective. COMIT II also will include
      analysis of fatty acid ethanolamines (FAEs) and their precursors to elucidate the mechanisms
      by which canola oil may be modifying body composition, measurement of endothelial function,
      inflammatory, adiposity and insulin sensitivity biomarkers, and genetic analyses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body composition</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Will be measured using DXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma lipids</measure>
    <time_frame>1 year 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow mediated dilation (FMD) for endothelial function</measure>
    <time_frame>1 year 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoprotein subclasses</measure>
    <time_frame>1 year 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>1 year 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid Peroxidation</measure>
    <time_frame>1 year 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of fatty acid inter-conversion and synthesis using stable isotope tracers</measure>
    <time_frame>1 year 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic analysis to evaluate the association between FADS 1 and FADS 2 mRNA and protein expression in peripheral blood mononuclear blood cells (PBMCs)</measure>
    <time_frame>1 year 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity level</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Will be assessed using an Actigraph GT3X+ activity monitor to be worn for 1 week at the end of each treatment period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Canola oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>regular canola oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High oleic acid canola oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high stability/high oleic canola oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Western diet oil combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a typical &quot;Western diet&quot; fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Canola Oil</intervention_name>
    <description>Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.</description>
    <arm_group_label>Canola oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High oleic acid canola oil</intervention_name>
    <description>High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.</description>
    <arm_group_label>High oleic acid canola oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Western diet oil combination</intervention_name>
    <description>A typical &quot;Western diet&quot; fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily</description>
    <arm_group_label>Western diet oil combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  waist circumference ≥94 cm for men and ≥80 cm for women

          -  Elevated triglycerides - ≥150 mg/dL and ≤ 400 mg/dL

          -  Reduced HDL - &lt; 40 mg/dL for men and &lt; 50 mg/dL for women

          -  Fasting glucose - ≥ 100 mg/dl and ≤ 126 mg/dL

          -  Elevated blood pressure - systolic ≥130 and/or diastolic ≥85 mm HG [Unmedicated
             participants - upper limit of Stage 1 Hypertension: systolic &lt; 160 and/or diastolic
             &lt;100 mm HG and participants must be free of end stage/target organ disease symptoms]
             [BP medicated participants: acceptable as long as individuals meet the specified blood
             pressure range of &lt;140/90 mmHg, and have been stable for at least 6 months]

        Exclusion Criteria:

          -  Individuals with thyroid**, kidney, or liver disease [Individuals with thyroid disease
             whose blood values are within normal limits and that have been stable (on medication)
             for the past 6 months are considered eligible]

          -  Individuals with diabetes mellitus

          -  Smokers

          -  Individuals consuming &gt;14 alcoholic beverages per week

          -  Individuals taking lipid lowering medication (ex: cholestyramine, colestipol, niacin,
             cloribrate, gemfibrozil, probucol, HMG CoA reductase inhibitors) for at least the last
             3 months

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny M Kris-Etherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny Kris-Etherton</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

